Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fenoldopam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 known ✓ | P21728 | 16/20 | 1.00 |
| ▸ | DRD2 | P14416 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenoldopam SCHEMBL34250 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL1815791 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL41214 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL9157427 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL1319766 | 0.99 | KDM4E (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL29424282 | 0.99 | DRD1 (0.97) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL9157381 | 0.99 | DRD1 (0.97) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL11215595 | 0.99 | KDM4E (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL16241872 | 0.99 | DRD1 (0.97) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL3136078 | 0.94 | GFER (0.91) | DRD1DRD2KDM4ERECQLBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485181-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-12-02 | — | — | US | claimed |
| US-12383625-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-12383626-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-20240316208-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | SERINA THERAPEUTICS (AL), INC. (US) | 2024-09-26 | — | — | US | claimed |
| US-20240293560-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | SERINA THERAPEUTICS (AL), INC. (US) | 2024-09-05 | — | — | US | claimed |
| US-20230009076-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | SERINA THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | US | claimed |
| CN-114258309-A | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | 塞瑞纳治疗公司 | 2022-03-29 | — | — | CN | claimed |
| CN-113164453-A | Cleavable conjugates of catechol compounds and water-soluble polymers and therapeutic methods using the same | 塞瑞纳治疗公司 | 2021-07-23 | — | — | CN | claimed |
| US-20210186957-A1 | Cleavable Conjugates of Catechol Compounds and Water-Soluble Polymers and Methods of Treatment Using the Same | SERINA THERAPEUTICS (AL), INC. | 2021-06-24 | — | — | US | claimed |
| EP-3829577-A1 | CLEAVABLE CONJUGATES OF CATECHOL COMPOUNDS AND WATER-SOLUBLE POLYMERS AND METHODS OF TREATMENT USING THE SAME | Serina Therapeutics, Inc. (US) | 2021-06-09 | — | — | EP | claimed |
| WO-2020023947-A1 | CLEAVABLE CONJUGATES OF CATECHOL COMPOUNDS AND WATER-SOLUBLE POLYMERS AND METHODS OF TREATMENT USING THE SAME | SERINA THERAPEUTICS, INC. (US) | 2020-01-30 | — | — | WO | claimed |
| US-20260131012-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | SERINA THERAPEUTICS (AL), INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12576034-B2 | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione | AMGEN INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12485181-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4378532-B1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2008150954-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION | WEINSTOCK JOSEPH (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20070066594-A1 | Crystalline forms fenoldopam mesylate | SICOR, INC. | 2007-03-22 | — | — | US | disclosed |
| WO-2005079851-A2 | DOPAMINE-AGONIST COMBINATION THERAPY WITH SEDATIVES FOR IMPROVING SLEEP QUALITY | SEPRACOR, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | CHRM2, ADRB2, CHRM3 | DRD1 61/4885DRD2 33/4885KDM4E 4465/4885 |
| US-12383625-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, SPOP, CYP2C19 | DRD1 675/4885DRD2 662/4885KDM4E 2755/4885 |
| US-20230009076-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | CYP3A5, CYP2C19, CYP3A7 | DRD1 610/4885DRD2 520/4885KDM4E 2757/4885 |
| US-12485181-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, CYP2C19, CYP3A7 | DRD1 610/4885DRD2 520/4885KDM4E 2757/4885 |
| US-20070066594-A1 | Crystalline forms fenoldopam mesylate | PDE5A, PDE3A, PDE6C | DRD1 2512/4885DRD2 2292/4885KDM4E 3168/4885 |
| US-20240293560-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | CYP3A5, SPOP, CYP2C19 | DRD1 675/4885DRD2 662/4885KDM4E 2755/4885 |
| US-20210186957-A1 | Cleavable Conjugates of Catechol Compounds and Water-Soluble Polymers and Methods of Treatment Using the Same | COMT, DBH, DNPEP | DRD1 92/4885DRD2 50/4885KDM4E 1527/4885 |
| US-12576034-B2 | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione | MAST1, HTR1D, MCTS1 | DRD1 648/4885DRD2 528/4885KDM4E 668/4885 |
| US-20260131012-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | CYP2C19, CYP2C9, CYP3A5 | DRD1 740/4885DRD2 949/4885KDM4E 2237/4885 |
| US-12383626-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, SPOP, CYP2C19 | DRD1 675/4885DRD2 662/4885KDM4E 2755/4885 |
| US-20240316208-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | CYP3A5, SPOP, CYP2C19 | DRD1 675/4885DRD2 662/4885KDM4E 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.